Oral Stent Device for Radiation Treatments of Oral Cancers

Author(s):  
2001 ◽  
Vol 28 (2) ◽  
pp. 169-173 ◽  
Author(s):  
K. Govind Babu
Keyword(s):  

2011 ◽  
Vol 1 (3) ◽  
pp. 188-195
Author(s):  
Rekha B. Pai ◽  
S. V. Kumaraswamy ◽  
R. M. Lalitha ◽  
N. Lalitha ◽  
S. Balakrishna Pai
Keyword(s):  

2017 ◽  
Vol 187 (1) ◽  
pp. 79-88 ◽  
Author(s):  
Rasha Elmghirbi ◽  
Tavarekere N. Nagaraja ◽  
Stephen L. Brown ◽  
Swayamprava Panda ◽  
Madhava P. Aryal ◽  
...  

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Alberto Fresa ◽  
Simona Sica

AbstractIt’s still not clear whether the mutational status of BRCA-mutated healthy hematopoietic stem cells (HSCs) donors could have an impact on the engraftment. Comparing the studies present in literature, we focused on the correlation between BRCA mutations and the development of hematological malignancies and Fanconi anemia (FA); then, we explored HSCs types, frequencies, and functions in the presence of BRCA mutations, as well as the reconstitution of hematopoiesis after chemotherapy and radiation treatments. The role of BRCA mutations in the FA showed a possible involvement in the onset of the disease; the mutation carriers, indeed, did not show any sign of the typical phenotype of the FA. BRCA mutational status can be considered as a risk factor for hematological malignancies, but only for secondary malignancies and/or in the presence of bone marrow stress factors. Currently we don’t know if a conditioning regimen could be compensated by BRCA mutated HSCs, even if murine models tried to show the possible differences between fully mutated, haploinsufficient and normal HSCs. Thus, given the downregulating effect of the mutations on hematopoiesis, it could be questionable to use the HSCs of a BRCA-mutated donor in the presence of another available donor with the same compatibility.


Oral ◽  
2021 ◽  
Vol 1 (2) ◽  
pp. 159-167
Author(s):  
Lucio Lo Russo ◽  
Eleonora Lo Muzio ◽  
Giuseppe Colella ◽  
Maria Eleonora Bizzoca ◽  
Vera Panzarella ◽  
...  

(1) Background: Gingival cancer has a significant incidence and is often diagnosed at advanced stages. The aim of this paper is to highlight its clinical aspects on the basis of a case series analysis in order to promote awareness and improve the diagnosis process. (2) Methods: Oral cancers diagnosed and treated at three Italian University Hospitals over ten years were retrospectively investigated. Cancer location on the gingiva, edentulous ridge, and retromolar pad was addressed. Data regarding clinical features, stage at the diagnosis, and time from presenting symptoms to first medical consultation were retrieved. (3) Results: Thirty-three cancers located on the gingiva, edentulous ridge, and retromolar pad were retrieved from 276 total oral cancer cases (11.9%). A median of 50 days (range 2–300) passed for the patient to seek for a medical evaluation. At the time of diagnosis, 63.3% were advanced stage cancers, mainly located at the mandible (91%), especially in the retromolar pad (48.5%) and the edentulous alveolar ridge (24.2%). Lesions were red (45.5%), red and white (45.4%), or white (9.1%), appearing as an ulcer (69.7%), exophytic mass (12.1%) or flat lesion (12.1%). Sixty-six percent of cancers were completely asymptomatic, regardless their clinical appearance. A statistically significant association between the time from the presentation of symptoms to the first medical consultation and the cancers stage was found. (4) Conclusions: The clinical appearance of gingival cancer is very polymorphous; its understanding may be significant to improve patient education and early medical consultation.


Oral Oncology ◽  
2020 ◽  
Vol 104 ◽  
pp. 104658 ◽  
Author(s):  
Abhishek Mahajan ◽  
Ankita Ahuja ◽  
Nilesh Sable ◽  
Hilda E. Stambuk

Author(s):  
Pooja Madki ◽  
Mandya Lakshman Avinash Tejasvi ◽  
Geetha Paramkusam ◽  
Ruheena Khan ◽  
Shilpa J.

Abstract Objectives The aim of the present study is to evaluate the role of immunoglobulins (IgA, IgG, and IgM) and circulating immune complexes (CIC) as tumor marker in oral cancer and precancer patients. Materials and Methods The present study was performed on 45 individuals subdivided into three groups, that is, oral precancer, oral cancer and healthy individuals, and levels of immunoglobulins, and CIC was estimated by turbidometry and ELISA method. Results In the present study, the mean serum IgA levels in oral precancer were 161.00 ( ±  118.02) mg/dL, oral cancers were 270.67 ( ±  171.44) mg/dL, and controls were 133.73 ( ±  101.31) mg/dL. Mean serum levels of IgG in oral precancer were 1,430.87 ( ±  316) mg/dL, oral cancers were 1,234.27 ( ±  365.42) mg/dL, and controls were 593.87 ( ±  323.06) mg/dL. Conclusion We found that the levels of serum IgG and IgA were elevated consistently in precancer and cancer group, and Serum IgM levels were increased only in precancer. Also, significant increase in serum CIC levels were seen in oral precancer and cancer group on comparison with control.


Sign in / Sign up

Export Citation Format

Share Document